Moreover, TAVO412 demonstrated efficacies in NSCLC and SCLC PDX models with stronger activities than amivantamab, an EGFR x c-Met bispecific antibody recently approved for EGFR Exon 20 insertion–driven NSCLC (13). Here, MET is linked to non-small cell lung carcinoma.